Petros Pharmaceuticals Inc

Petros Pharmaceuticals Inc (PTPI) Stock Analysis

$0.066

-0.031 (-46.45%)At close

Loading chart…
High
0.085
Open
0.065
VWAP
0.07
Vol
266.56M
Mkt Cap
3.12M
Low
0.060
Amount
18.79M
EV/EBITDA, TTM
0.00

Petros Pharmaceuticals, Inc. is focused on the self-care market by providing expanded access to key prescription pharmaceuticals such as OTC treatment options. The Company is engaged in developing a software-as-a-service (SaaS) platform designed to assist pharmaceutical companies in meeting FDA standards to assist in the Rx-to-OTC switch. In addition to the SaaS component, the platform is intended to incorporate software as a medical device (SaMD) capabilities, transforming traditional OTC medications into digitally enabled solutions. The SaMD interface seeks to be designed as customized and branded to pharmaceutical therapy and established as a specific application pathway to that therapy. Together, it aims to develop the SaaS and SaMD components to create a scalable, licensable platform that supports various classes of medications across the pharmaceutical industry, assisting pharmaceutical companies achieve regulatory approval, while delivering consumer-focused healthcare solutions.

Valuation Metrics

The current forward P/E ratio for Petros Pharmaceuticals Inc (PTPI) is -0.08, compared to its 5-year average forward P/E of -0.22.

Forward P/E

Fair
5Y Average P/E
-0.22
Current P/E
-0.08
Overvalued
0.02
Undervalued
-0.47

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued
0.00
Undervalued
0.00

Forward P/S

Fair
5Y Average P/S
0.39
Current P/S
0.38
Overvalued
0.75
Undervalued
0.04

Events Timeline

2025-06-25 (ET)

09:16:47

Petros Pharmaceuticals announces deconsolidation of Metuchen subsidiary

2025-05-21 (ET)

09:12:51

Petros Pharmaceuticals announces transition from Nasdaq to OTC Markets

2025-05-20 (ET)

09:23:05

Petros Pharmaceuticals partners with Innolitics

2025-05-06 (ET)

09:22:32

Petros Pharmaceuticals strengthens partnership with big data provider

2025-05-01 (ET)

09:29:51

Petros Pharmaceuticals developing SaaS Platform using AI, EHR

News

PTPI FAQ — answered by Alphio AI

Petros Pharmaceuticals, Inc. is focused on the self-care market by providing expanded access to key prescription pharmaceuticals such as OTC treatment options. The Company is engaged in developing a software-as-a-service (SaaS) platform designed to assist pharmaceutical companies in meeting FDA standards to assist in the Rx-to-OTC switch. In addition to the SaaS component, the platform is intended to incorporate software as a medical device (SaMD) capabilities, transforming traditional OTC medications into digitally enabled solutions. The SaMD interface seeks to be designed as customized and branded to pharmaceutical therapy and established as a specific application pathway to that therapy. Together, it aims to develop the SaaS and SaMD components to create a scalable, licensable platform that supports various classes of medications across the pharmaceutical industry, assisting pharmaceutical companies achieve regulatory approval, while delivering consumer-focused healthcare solutions. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started